Aim: In contrast to significant advances in organ preservation in locally advanced rectal cancer, the contemporary management of early-stage rectal cancer, including the frequency of abdominoperineal resections, remains largely unexplored in the United States. Therefore, we assessed the utilization of neoadjuvant therapy and oncological resections in early-stage rectal cancer patients.
Study Design: This is a retrospective cohort study of patients with cT1-T3N0 rectal cancer who underwent proctectomies between 2016 and 2022 in the National Surgical Quality Improvement Project proctectomy files.
The clinical effects on the udder health of several trace elements-copper, iodine, cobalt, and selenium-contained in an intraruminal slow-release bolus were explored for the first time. Fifty-four dairy cows received the bolus (treated group, TG), while fifty-three were left untreated (control group, CG). Monthly composite milk samples were collected from 30 to 300 days in milk to measure somatic cell count (SCC); milk production was also recorded on the same days.
View Article and Find Full Text PDFImportance: Close surveillance for detection of local tumor regrowth is critical for patients opting for nonoperative management after neoadjuvant therapy for rectal cancer. However, there are minimal data regarding the feasibility and adherence to National Comprehensive Cancer Network (NCCN) surveillance guidelines for these patients.
Objective: To determine adherence rates to NCCN-recommended surveillance in patients undergoing nonoperative management for rectal cancer.